Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis

Chronic Plaque-type Psoriasis Clinical Trial

Official title:
A Randomized, Double-blind, Placebo and Positive Controlled, Single and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CJM112 in Chronic Plaque-type Psoriasis Patients

Status Completed

Clinical Trial Summary

A randomized, double-blind, placebo and positive controlled, single and multiple dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CJM112 in chronic plaque-type psoriasis patients. This trial never made it to the Phase II part of this trial.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01828086
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 1
Start date	June 2013
Completion date	October 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01071252` - A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis	Phase 2
Completed	`NCT00941031` - AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis	Phase 2
Completed	`NCT04207801` - A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis	Phase 2
Completed	`NCT03553823` - Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab	Phase 2